Cancer is one of the most serious diseases in man and the second most fatal disease, after atherosclerosis. Breast cancer is the most common cancer among African American women, Recently, interest in herbal extracts for the prevention and treatment of this disease has increased, for such extracts are considered to be safe, economically feasible, and effective. Withania somnifera (WS), commonly known as ashwagandha, has been used for many years in traditional medicine, especially in the treatment of human tumors, arthritis, and stress. This small, woody shrub, which grows about two feet in height, is found in Africa, the Mediterranean, India, and the United States, where it is known as winter cherry. Preliminary data from our laboratory, obtained on a previous pilot project, funded by the MSM/TU/UAB CCC Partnership, show that daily administration of a root extract of WS (given as an oral dose of 300 mg/kg for 21 days) causes 99% grovrth inhibition of breast cancer cells xenografted in mice. The main goal of this proposal is to determine a safe and efficacious dose of WS for use in rats for chemoprevention in methylnitrosourea (MNU)-induced mammary tumors and in mice for therapy of xenografted breast cancer cells. In addition, the effect of the WS root extract, alone and in combination with tamoxifen, will be evaluated in a panel of breast cancer cell lines in vitro. The molecular effects of WS extract will be evaluated by using slices of tumors obtained from treated animals and breast cancer cells exposed to the extract.

Public Health Relevance

This Study could provide a basis for the clinical use of a safe and efficacious anti-tumor drug. By reducing the doses of standard drugs and the cost of treatment, such a drug could provide effective therapy and also reduce the suffering of breast cancer patients caused by the side effects of currently used anti-cancer medicines and treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA118948-07
Application #
8555474
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Project Start
2005-09-30
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
7
Fiscal Year
2012
Total Cost
$42,382
Indirect Cost
$15,131
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications